Vaccine manufacture at the time of a pandemic influenza
- PMID: 7843364
- DOI: 10.1007/BF01719684
Vaccine manufacture at the time of a pandemic influenza
Abstract
In the event of a major influenza epidemic, the availability of a potent and safe vaccine would be a major concern. The following presentation describes the main features of a flu vaccine manufacturing campaign: beginning with the supply of embryonated eggs, in which the flu viruses are cultivated, through the different steps of vaccine production - egg harvest, purification, inactivation, splitting - down to the final vaccine formulation and aseptic filling in the appropriate containers. In usual times, such a production cycle takes over 70 weeks. In an emergency situation, the manufacturers and the authorities would have to take innovative approaches to minimize such delays. This will inevitably translate into an enormous strain on all the players in such a project, from the egg suppliers to the organisers of the vaccine dispatching and administration. It will result in suboptimal yields and costs. However, facing a massive and urgent need of vaccine, both the authorities and the vaccine manufacturers must work together to supply the necessary doses in time.
Similar articles
-
Open debate could slow flu vaccine production.Nature. 2008 Aug 21;454(7207):939. doi: 10.1038/454939c. Nature. 2008. PMID: 18719565 No abstract available.
-
Norway: problems which a small and sparsely populated European country without a national vaccine production would face during a pandemic.Eur J Epidemiol. 1994 Aug;10(4):519-21. doi: 10.1007/BF01719694. Eur J Epidemiol. 1994. PMID: 7843374
-
Development of a mammalian cell (Vero) derived candidate influenza virus vaccine.Vaccine. 1998 May-Jun;16(9-10):960-8. doi: 10.1016/s0264-410x(97)00301-0. Vaccine. 1998. PMID: 9682344
-
From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza.Nat Rev Microbiol. 2004 Oct;2(10):842-7. doi: 10.1038/nrmicro979. Nat Rev Microbiol. 2004. PMID: 15378048 Review.
-
Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.Drugs R D. 2003;4(5):312-9. doi: 10.2165/00126839-200304050-00007. Drugs R D. 2003. PMID: 12952502 Review.
Cited by
-
Strategies for Vaccine Prioritization and Mass Dispensing.Vaccines (Basel). 2021 May 14;9(5):506. doi: 10.3390/vaccines9050506. Vaccines (Basel). 2021. PMID: 34068985 Free PMC article.
-
Respiratory illnesses in Canadian health care workers: a pilot study of influenza vaccine and oseltamivir prophylaxis during the 2007/2008 influenza season.Influenza Other Respir Viruses. 2011 Nov;5(6):404-8. doi: 10.1111/j.1750-2659.2011.00245.x. Epub 2011 Apr 5. Influenza Other Respir Viruses. 2011. PMID: 21668681 Free PMC article. Clinical Trial.
-
Universal vaccination of healthy children against influenza: a role for the cold-adapted intranasal influenza vaccine.Paediatr Drugs. 2002;4(1):65-71. doi: 10.2165/00128072-200204010-00007. Paediatr Drugs. 2002. PMID: 11817987 Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical